About
David Grainger, a former Cambridge academic and Nature/Science-published scientist, co-founds asset‑centric single‑program biotechs, combines R&D leadership with operational experience, and writes on pharma R&D and deals for DrugBaron and Forbes.
Invests in
BiotechDeep TechDigital HealthHealthtechMedical Devices
Investments
Led
Padlock TherapeuticsXO1
Board seats
Morphogen-IXRivus PharmaceuticalsZ-Factor
Per the firm's website.